Four biotech companies announce pricings of IPOs, looking to raise more than $300M
NextCure, Milestone Pharmaceuticals, Cortexyme and Axcella Health all said Wednesday that they would begin trading on the Nasdaq Thursday.
NextCure, Milestone Pharmaceuticals, Cortexyme and Axcella Health all said Wednesday that they would begin trading on the Nasdaq Thursday.
Cortexyme has also finished enrolling healthy volunteers in the Phase I study of lead candidate COR388.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A wearable device that could transform how physicians diagnose the underlying causes of GI disorders is one of three innovative early stage life science companies Peter Thiel’s Breakout Labs is backing. The program from the Thiel Foundation provides up to $350,000 for companies to reach certain milestones critical to their development, according to a company […]